Trial Profile
A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Oct 2010 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Sep 2006 to Oct 2006 as reported by ClinicalTrials.gov.
- 14 Oct 2008 Trial phase changed from III to IV as reported by ClinicalTrials.gov.